Epkinly Granted Accelerated FDA Approval for Lymphoma

MONDAY, May 22, 2023 -- The U.S. Food and Drug Administration has granted accelerated approval to Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and...